Arrowhead Wins EU Approval for REDEMPLO® in Rare Lipid Disease
PASADENA, Calif., June 22, 2026 Arrowhead Pharmaceuticals has reached a major regulatory milestone after the European Commission (EC) granted...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PASADENA, Calif., June 22, 2026 Arrowhead Pharmaceuticals has reached a major regulatory milestone after the European Commission (EC) granted...
LONDON, June 25, 2026 Evaluate, a Norstella company and a leading provider of pharmaceutical market intelligence, has been recognized...
